Belgian National Institute for Health and Disability Insurance (INAMI-RIZIV) temporarily reimburses gene expression profile (GEP) testing for early-stage breast cancer detection under a specific convention that was valid from July 01, 2019, to June 30, 2022. INAMI-RIZIV announced that it will be extended until December 31, 2022. The list of reimbursable tests, reimbursement amount, and other conditions remains the same.
Molecular biology tests by next-generation sequencing (NGS) are temporarily reimbursed by INAMI-RIZIV under a specific convention that was valid from July 01, 2019, to June 30, 2022. INAMI announced that it will be extended until June 30, 2023. The reimbursement supplements per indications are specified in Annex 4, which was updated on June 30, 2022. Other conditions remain the same.
See the full details in French and Dutch here (for GEP) and here (for NGS).
This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.
Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).